Tailoring treatment in ovarian cancer

June 11, 2014, University College Dublin
MAD2 immunostaining patterns in epithelial ovarian carcinomas (EOC) (a) Perinuclear MAD2 immunostaining in a moderately differentiated clear cell carcinoma (magnification x40 objective), (b) Cytoplasmic and nuclear MAD2 immunolocalisation in a moderately differentiated serous carcinoma (magnification x40 objective).  ‌

(Medical Xpress)—The prognosis for ovarian cancer patients is poor with only 3 out of 10 women living at least 5 years after diagnosis. Clinicians urgently need the tools to provide a more accurate prognosis for patients in terms of whether particular chemotherapeutic agents will be of benefit in their treatment.

UCD researchers led by Dr Amanda McCann have now identified the protein MAD2 as a potential prognostic marker in a number of histological subtypes of ovarian cancer. This may help provide more tailored approaches to the treatment of ovarian cancer patients.

MAD2 is one of the protein components of the spindle assembly checkpoint (SAC) present in all eukaryotes that prevents chromosomes from segregating incorrectly during cell division.
Paclitaxel (Taxol) is the first-line used to treat in combination with platinum agents. It works by interfering with the spindle microtubule dynamics to cause cell cycle arrest and cell death (apoptosis), a function mediated by MAD2.

"In this study, we were able to show that low MAD2 nuclear expression associates with a poorer response to chemotherapy and this was exemplified by a shorter time to recurrence of the disease in the patient cohort whose cancer subtype included serous, endometrioid and mixed histologies", explained Barbara McGrogan, the lead author and doctoral candidate in the McCann group.

Serous and endometrioid tumours are biologically different, however, in clinical practice they are still treated similarly. Dr McCann said, "The fact that decreased MAD2 nuclear expression identifies those women with a shorter recurrence free survival irrespective of histological subtype and could help guide clinicians as to whether chemotherapy will actually benefit the patient."

Explore further: Predicting cellular response to paclitaxel in epithelial ovarian cancer

More information: McGrogan B, Phelan S, Fitpatrick P, Maguire A, Prencipe M, Brennan D, Doyle E, O'Grady A, Kay E, Furlong F, McCann A. Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. Hum Pathol. 2014 Mar 27. pii: S0046-8177(14)00121-X. DOI: 10.1016/j.humpath.2014.03.004. [Epub ahead of print] PubMed PMID: 24792619. 

Related Stories

Predicting cellular response to paclitaxel in epithelial ovarian cancer

November 16, 2011
(Medical Xpress) -- New research findings by UCD scientists published online in the Journal of Pathology may help clinicians predict how patients with high grade, serous, epithelial ovarian cancer will respond to paclitaxel ...

Biomarkers predict time to ovarian cancer recurrence

August 15, 2013
Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated ...

Study links endometriosis with increased risk of developing 3 specific types of ovarian cancer

February 21, 2012
Women with a history of endometriosis are significantly more likely to develop three specific types of ovarian cancer (clear cell, endometrioid, and low-grade serous), according to an article published Online First in the ...

Researchers find way to decrease chemoresistance in ovarian cancer

May 2, 2014
Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say.

Disease-free survival estimates for ovarian cancer improve over time

April 4, 2014
The probability of staying disease-free improves dramatically for ovarian cancer patients who already have been disease-free for a period of time, and time elapsed since remission should be taken into account when making ...

Ovarian cancer subtypes may predict response to bevacizumab

June 1, 2014
Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the ...

Recommended for you

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.